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Purpose: To compare the anatomic and functional efﬁcacy and safety of half-dose photodynamic therapy
(PDT) versus high-density subthreshold micropulse laser (HSML) treatment in patients with chronic central serous
chorioretinopathy (cCSC).
Design: Open-label, multicenter, randomized controlled clinical trial.
Participants: Patients with cCSC whose disease had to be conﬁrmed by both clinical characteristics and
ﬁndings on multimodal imaging.
Methods: Eligible patients were randomized in a 1:1 allocation ratio. Treatment was evaluated during a
follow-up visit, and the same treatment was repeated in patients who still demonstrated subretinal ﬂuid (SRF).
Main Outcome Measures: The primary end point was the complete disappearance of SRF at the ﬁrst
evaluation visit at 6 to 8 weeks after treatment. As a secondary outcome measure, we assessed this anatomic
result at the ﬁnal evaluation visit at 7 to 8 months after treatment. Other secondary outcomes covered functional
improvement and included change in best-corrected visual acuity (BCVA; measured in Early Treatment Diabetic
Retinopathy Study [ETDRS] letters), retinal sensitivity (measured using microperimetry), and vision-related quality
of life using a validated questionnaire.
Results: Between November 2013 and September 2016, 179 patients were included: 89 patients were
assigned randomly to half-dose PDT, and 90 were assigned randomly to HSML treatment. At their ﬁrst evaluation
visit, SRF had resolved in 51.2% and 13.8% of patients, respectively (P < 0.001). At their ﬁnal evaluation visit, a
signiﬁcantly higher percentage of PDT-treated patients demonstrated no SRF (67.2% vs. 28.8%; P < 0.001).
Moreover, at the ﬁrst evaluation visit, the PDT-treated patients showed a signiﬁcantly higher increase in BCVA
(þ4.606.62 ETDRS letters vs. þ1.398.99 ETDRS letters; P ¼ 0.011), and a signiﬁcantly higher increase in
retinal sensitivity on microperimetry (þ2.013.04 dB vs. þ0.923.65 dB; P ¼ 0.046); however, the improvement
in vision-related quality of life was similar (score of þ2.878.35 vs. þ2.567.36, respectively; P ¼ 0.800).
Conclusions: Half-dose PDT is superior to HSML for treating cCSC, leading to a signiﬁcantly higher pro-
portion of patients with complete resolution of SRF and functional improvement. Ophthalmology 2018;125:1547-
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ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Supplemental material available at www.aaojournal.org.
Central serous chorioretinopathy (CSC) is a relatively
common chorioretinal disease associated with a sudden
loss of central vision. Although the cause of CSC is
currently unknown, it affects primarily middle-aged men
and is associated with corticosteroid use, stress, and certain
genetic susceptibility factors.1e3 In CSC, congestion,
hyperpermeability, and thickening of the choroid lead to
impaired function of the retinal pigment epithelium (RPE),
which normally maintains the outer blooderetina barrier.
The resulting loss of integrity in this barrier leads to the
accumulation of subretinal ﬂuid (SRF), which leads to
marked central vision loss, primarily affecting the macula.1
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In acute CSC, sudden-onset loss of central vision occurs
because of a single point of leakage in the RPE; such cases
tend to resolve spontaneously within several months.1
However, at least 15% of patients with CSC have chronic
SRF accumulation, with associated persistent vision loss
and more extensive pathologic features of the retina and
choroid. In these cases of chronic CSC (cCSC), persistent
SRF can lead to progressive and irreversible damage to
photoreceptors, resulting in both a guarded visual
prognosis and a decline in quality of life among these
relatively young patients.4e6 Although the efﬁcacy of a
variety of treatment methods for cCSC has been evaluated
retrospectively, no evidence-based consensus regarding the
optimal clinical management of cCSC currently exists
because of a lack of large prospective, randomized controlled
treatment trials.1,7 The 2 most commonly performed treat-
ments for cCSC are photodynamic therapy (PDT) with ver-
teporﬁn (Visudyne (Novartis, Basel, Switzerland)),
originally developed to treat age-related macular degenera-
tion,8 and high-density subthreshold micropulse laser
(HSML) treatment. Although both treatments have reported
anatomic success rates (i.e., complete resolution of SRF) of
41% to 100% and a favorable safety proﬁle,1,7,9e15 there is
currently no consensus with respect to which intervention
may be more effective. For example, in the United Kingdom,
the National Health Service has not approved either of these
treatments for cCSC. Herein, we report the results of the
Half-Dose Photodynamic Therapy versus High-Density
Subthreshold Micropulse Laser Treatment in Patients with
Chronic Central Serous Chorioretinopathy (PLACE) trial, a
prospective multicenter study of patients with cCSC in
which we directly compared both safety and efﬁcacy be-
tween half-dose PDT and HSML treatment.
Methods
Study Design
The PLACE trial was an investigator-initiated, open-label, multi-
center, randomized controlled treatment trial conducted at 5
academic medical centers in 4 European countries. The study was
performed in accordance with the tenets of the Declaration of
Helsinki, and all participating centers received approval from their
respective institutional review board and ethics committee (clin-
icaltrials.gov identiﬁer, NCT01797861). The protocol has been
published previously.16
Participants
In this trial, we enrolled both men and women 18 years of age or
older with cCSC, based on both clinical characteristics and ﬁndings
on multimodal imaging. On multimodal imaging, SRF that affected
the fovea visible on spectral-domain OCT scan (Fig 1A), 1 or more
regions of active leakage (so-called hot spots) combined with RPE
window defects visible on ﬂuorescein angiography (FA; Fig 1B),
and hyperﬂuorescent changes typical of cCSC visible on
indocyanine green angiography (ICGA; Fig 1C) were mandatory
to be eligible for inclusion. In addition, SRF on OCT, subjective
visual symptoms related to cCSC, or both had to be present for
at least 6 weeks for inclusion in the study. Subretinal ﬂuid did
not need to include the fovea at the ﬁrst evaluation visit for the
patient to be eligible for treatment, provided there was persistent
SRF in the macula, which was interpreted as persistent active
disease. Study eye exclusion criteria included previous treatment
for active CSC in the study eye; evidence of any other diagnosis
that could explain SRF or vision loss; best-corrected visual
acuity (BCVA) of 20/200 or worse (Snellen equivalent); profound
chorioretinal atrophy in the central macular area visible on
ophthalmoscopy and OCT; myopia exceeding 6 diopters; contin-
uous or progressive vision loss, or both, SRF, or a combination
thereof (visible on OCT) for more than 18 months; absence of
active leakage visible on FA; absence of hyperﬂuorescence on
ICGA; presence of soft drusen in the study eye, other eye, or both;
and signs of choroidal neovascularization visible on ophthalmos-
copy, FA, ICGA, or a combination thereof. Moreover, CSC pa-
tients with intraretinal ﬂuid on OCT were not included in the study
because this is often viewed as evidence of prolonged disease with
more pronounced irreversible structural and functional changes,
which may lead to a decreased response to treatment.17 More
importantly, it may be difﬁcult in CSC cases with intraretinal
ﬂuiddespecially without OCT angiography, which was not
available at the time of the start of the studydto exclude
neovascularization deﬁnitely. Nonocular exclusion criteria
included current topical or systemic treatment with corticosteroids,
corticosteroid use within 3 months before the initial trial treatment,
an anticipated start of corticosteroid treatment within the ﬁrst 7 to 8
months after the start of the trial period, contraindications for PDT
treatment (e.g., pregnancy, porphyria, or severely reduced liver
function), and contraindications for FA or ICGA (e.g., known
allergies, particularly to shellﬁsh, previous reactions). Eligible
patients were identiﬁed and counselled in their respective
participating hospitals. Written informed consent was obtained from
each patient before participation.
Randomization and Masking
Patients were assigned randomly (at a 1:1 ratio) to receive either
half-dose PDT or HSML treatment. Randomization was performed
using a central computerized procedure using block randomization
with alternating block sizes of 4, 5, and 6, with stratiﬁcation on the
including hospitals, and without minimization. We did not take
baseline characteristics of our patients into account before
randomization, which can be considered to be standard for this type
of study. The Department for Health Evidence at the Radboud
University Medical Center performed the randomization proced-
ure. Because of the nature of the interventions, neither the clinical
staff nor the patients could be blinded with respect to the treatment
group.
Procedures
Each patient’s demographic characteristics andmedical history were
documented at the baseline visit. An extensive ophthalmologic
examination was performed, including assessing Early Treatment
Diabetic Retinopathy Study (ETDRS) BCVA, retinal sensitivity
(measured using microperimetry), and vision-related quality of life
(measured using the validated 25-item National Eye Institute Visual
Function Questionnaire [NEI-VFQ25]).18 Microperimetry was
measured using 2 different devices, the MP1 (Nidek Technologies,
Padova, Italy) and the Macular Integrity Assessment (CenterVue,
Padova, Italy); a previously published conversion method then
was applied to obtain values with the same dynamic range.19
Fundus photography, OCT, fundus autoﬂuorescence, ﬂuorescein
angiography, and ICGA imaging were performed by certiﬁed
medical photographers. After eligibility was determined by a
central reading center, patients were assigned randomly to the
treatment groups and then received either half-dose PDT or HSML
treatment within 3 weeks of randomization. For each treatment
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method, the ocular area to be treated was determined by the central
reading center based on the hyperﬂuorescent areas of leakage seen
on ICGA to avoid interobserver variability on the interpretation of
the extent these choroidal abnormalities. This approach was used
because ICGA-guided therapy targets the primary affected tissue
(i.e., the choroid) and decreases the risk of undertreatment because
ICGA generally reveals more extensive abnormalities compared
with FA (Fig 1). Care was taken to include the focal area(s) of
Figure 1. Example images from a 48-year-old man with chronic central serous chorioretinopathy showing the areas that would be treated using half-dose
photodynamic therapy (PDT) and the areas that would be treated using high-density subthreshold micropulse laser (HSML). A, OCT image showing
subretinal ﬂuid (arrow). B, Fluorescein angiography image showing a hot spot of leakage (white arrow) as well as retinal pigment epithelium abnormalities
(black arrow). C, Indocyanine green angiography image showing hyperﬂuorescent changes in the choroid; the arrow indicates the most evident changes,
which extend more superiorly; the fovea is indicated by the white circle. D, Indocyanine green angiography image showing the area that would be treated
using half-dose PDT, indicated by the black circle. E, Indocyanine green angiography image showing the area that would be treated using HSML treatment,
indicated by small black circles. Note that the area depicted for HSML treatment is a schematic representation only; the actual nonoverlapping adjacent
spots relative to the fundus are smaller than depicted here.
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leakage on FA in the treatment area. All diagnostic and therapeutic
devices were maintained and serviced by certiﬁed personnel at the
participating centers in accordance with the manufacturers’
instructions.
Verteporﬁn was developed initially for PDT-based treatment of
neovascular age-related macular degeneration; however, it is now
used commonly as an off-label medication for treating cCSC.7,8 A
safety-enhanced protocol, in which half the dosage of verteporﬁn is
used, has been shown to induce the desired treatment outcome in a
similar percentage as after performing PDT using full-dose verte-
porﬁn, but reducing the occurrence of adverse events (AEs).11,20
Patients in the half-dose PDT group received an intravenous
infusion of 3 mg/m2 verteporﬁn delivered over a period of 10
minutes. Exactly 15 minutes after the start of this infusion, a
contact lens was positioned on the eye, the treatment spot was
centered using predeﬁned criteria for ICGA-guided treatment, and
PDT was applied using standard parameters (ﬂuency, 50 J/cm2;
wavelength, 689 nm; and treatment duration, 83 seconds). Where
necessary, the fovea was included in the area to be treated. In the
HSML-treated group, several adjacent nonoverlapping spots were
applied during ICGA-guided treatment using an 810-nm diode
laser, keeping a distance of 500 mm from the foveal center. To
minimize the likelihood of undertreatment, a relatively high power
of 1800 mW (which is considered to be within the upper range of
subthreshold settings) was applied to a relatively large ICGA-
guided treatment area.21 In addition, the duty cycle was 5%, the
frequency was 500 Hz, the exposure time was 0.2 seconds per
spot, and the spot size was 125 mm. Because subthreshold
treatment was desired, the power of the treatment was reduced in
300-mW increments if any retinal discoloration was visible after
a test treatment spot was applied outside the macular area, at the
beginning of the procedure. All laser operators in the study (S.F.,
J.E.E.K., P.J.H.P., G.D., E.H.S., R.E.M., G.Q., S.M.D.) underwent
formal training and were approved by the chief investigator
(C.J.F.B.).
In patients in whom SRF was still present within the macular
area at evaluation 6 to 8 weeks after treatment (i.e., at the ﬁrst
evaluation visit), the same treatment was repeated, which is often
considered to be part of standard care, and a second evaluation visit
was scheduled 6 to 8 weeks after this second treatment. All patients
underwent a ﬁnal evaluation visit 7 to 8 months after the ﬁrst
treatment. At each evaluation visit, the patients underwent a
complete ophthalmologic examination and imaging as described
previously.
Outcomes
The primary outcome measure was the complete absence of SRF
on OCT (anatomic success) at the ﬁrst evaluation visit (i.e., 6 to 8
weeks after the ﬁrst treatment). In addition, the following protocol-
deﬁned key secondary outcome measures in both the half-dose
PDT group and the HSML treatment group were assessed: a
complete absence of SRF on OCT at the ﬁnal evaluation visit; the
number of repeat (i.e., second) treatments needed in each treatment
arm; and the change in ETDRS BCVA, retinal sensitivity on
microperimetry, and vision-related quality of life measured using
the NEI-VFQ25, from baseline to both ﬁrst and ﬁnal evaluation
visits. Adverse events and serious AEs were reported to the data
safety monitoring board, which had the option to terminate the
study prematurely if deemed necessary.
Statistical Analysis
This randomized controlled trial was designed to be a superiority
study. We calculated that a sample size of 156 patients (78 in each
group) would be required at the ﬁrst evaluation visit to detect a
difference of 22% in treatment success with a power of at least
80%; this calculation was based on previously published retro-
spective studies regarding PDT and HSML treatment in cCSC,
possible positive publication bias, our own empirical experience,
and an interim analysis.1,7,11,12,14
Statistical analysis on the primary outcome measure was per-
formed using a cross-table to assess the relative risk. The key
secondary analyses, complete absence of SRF on OCT at the ﬁnal
evaluation visit and number of repeat treatments needed in each
treatment arm, also were performed using a cross-table. Contin-
uous secondary end points were analyzed using an analysis of
covariance with baseline and treatment as factors. Categorical
secondary variables were analyzed using a chi-square test. Changes
in the replies to the NEI-VFQ25 are reported using a scale ranging
from 0 to 100, as described previously.18 The PLACE trial was
registered internationally with ClinicalTrials.gov (identiﬁer,
NCT01797861) and was assigned the EudraCT number 2012-
004555-36.
Results
We initially screened a total of 309 patients for eligibility; after
applying the inclusion and exclusion criteria, 179patients (89 patients
in the PDT treatment arm and 90 patients in theHSML treatment arm)
were determined to be eligible and were enrolled between November
2013 and September 2016 (Fig 2). Eighty patients in each treatment
arm underwent their respective treatment in accordance with the
study protocol (Fig 2). Because of the presence of SRF at the ﬁrst
evaluation visit, 108 of the original 160 patients (67.5%)
underwent repeat treatment. Six patients who would have required
repeat treatment based on the protocol did not receive this second
treatment (Fig S1, available at www.aaojournal.org), and 1 patient
was excluded from the trial after the ﬁrst evaluation visit because
of corticosteroid use. Two patients did not attend the second
evaluation visit, but did attend the ﬁnal evaluation visit. Nineteen
patients did not attend the ﬁnal evaluation visit. In total, 67 and 66
patients in the half-dose PDT and HSML groups, respectively,
were analyzed after their ﬁnal evaluation visit (Fig 2).
The baseline characteristics were balanced between the 2
groups (Table 1). Speciﬁcally, there was no signiﬁcant difference
between the half-dose PDT group and the HSML-treated group
with respect to BCVA (76.98.32 ETDRS letters vs. 75.99.22
ETDRS letters, respectively; P ¼ 0.478), retinal sensitivity
measured using microperimetry (20.54.21 dB vs. 20.34.80 dB,
respectively; P ¼ 0.755), or vision-related quality of life measured
using the NEI-VFQ25 (81.213.0 points vs. 83.111.5 points,
respectively; P ¼ 0.158).
At the ﬁrst evaluation visit, a signiﬁcantly higher percentage of
patients in the PDT-treated group showed complete resolution of
SRF (the primary outcome measure) compared with the HSML-
treated group (51.2% vs. 13.8%, respectively; P < 0.001). After
HSML treatment, the relative risk of persistent SRF at the ﬁrst
evaluation visit after HSML treatment was 1.77 (95% conﬁdence
interval, 1.39e2.52) compared with receiving half-dose PDT.
At the ﬁnal evaluation visit, a signiﬁcantly higher percentage of
patients in the PDT group showed complete resolution of SRF
compared with the HSML-treated group (67.2% vs. 28.8%,
respectively; P < 0.001), and the relative risk of persistent SRF at
the ﬁnal evaluation visit after HSML treatment was 2.17 (95%
conﬁdence interval, 1.49e3.16) compared with receiving half-dose
PDT (Table 2).
In the half-dose PDT group, the mean PDT laser spot size for
the ﬁrst and second treatments was 4.011.57 mm and 4.041.54
mm, respectively. In the HSML treatment group, 187209 spots
with a mean power of 1739213 mW were applied at the ﬁrst
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treatment, and 188237 spots with a mean power of 1746184
mW were applied at the second treatment. A total of 99 patients
required a second evaluation visit because of undergoing repeat
treatment based on the presence of SRF measured on OCT at the
ﬁrst evaluation visit; during the second evaluation visit, 32.4% of
patients (11 of 34 patients) and 15.4% of patients (10 of 65
patients) in the half-dose PDT group and HSML group, respec-
tively, showed complete resolution of SRF on OCT; however, this
difference was not statistically signiﬁcant (P ¼ 0.053).
At the ﬁrst evaluation visit, the patients in the half-dose PDT
group showed a signiﬁcantly higher increase in BCVA compared
with the HSML treatment group (4.606.62 ETDRS letters vs.
1.398.99 ETDRS letters, respectively; P ¼ 0.011). At the ﬁnal
evaluation visit, the increase in BCVA relative to baseline was
6.788.54 ETDRS letters and 4.487.29 ETDRS letters in the
PDT and HSML groups, respectively (P ¼ 0.099). Retinal sensi-
tivity on microperimetry increased in both treatment groups, and
this increase was signiﬁcantly higher in the PDT group compared
with the HSML-treated group at both the ﬁrst evaluation visit
(2.013.04 dB vs. 0.923.65 dB, respectively; P ¼ 0.046) and the
ﬁnal evaluation visit (3.243.08 dB vs. 1.384.45 dB, respec-
tively; P ¼ 0.008). Finally, the change in vision-related quality of
life measured using the NEI-VFQ25 increased in both groups;
however, this increase did not differ signiﬁcantly between the
PDT- and HSML-treated groups at either the ﬁrst evaluation visit
(2.878.35 points vs. 2.567.36 points, respectively; P ¼ 0.800)
or the ﬁnal evaluation visit (7.0310.8 points vs. 4.489.85
points, respectively; P ¼ 0.158; Table 2).
During the course of the trial, SRF recurred in 4 patients in the
PDT group and 1 patient in the HSML group (corresponding to 5%
and 1.3% of patients, respectively; P ¼ 0.176). Twelve AEs were
recorded in 10 patients in the PDT group, and 9 AEs were recorded
in 7 patients in the HSML group (corresponding to 12.5% and
8.8% of patients, respectively). None of these AEs were treatment
related. A total of 4 patients (2 each in the PDT and HSML groups)
reported a serious AE that was unrelated to the study treatment, and
none of the patients died during the trial. One patient in the HSML
group demonstrated a vision-threatening AE in which BCVA
decreased by more than 30 ETDRS letters; this decline in visual
acuity was considered to have been caused by an increase in SRF,
despite treatment. All of the side effects reported in this trial are
listed in Table 3.
Discussion
Treatment usually is indicated for patients with cCSC,
because persistent SRF leakage in the macula can lead to
signiﬁcant visual disability and decreased vision-related
quality of life.1,5 To date, however, the best treatment for
cCSC has been the subject of controversy because of a lack of
prospective randomized controlled trials, leading to a wide
variety of recommended treatments.1,7,22 Herein, we per-
formed a large prospective, multicenter, randomized
controlled treatment trial comparing the 2 most commonly
used treatments for cCSC.1,7,11,12,14 We found that the efﬁ-
cacy of half-dose PDT with respect to complete resolution of
SRF was signiﬁcantly higher compared with HSML
Figure 2. Flow diagram showing the trial proﬁle for the primary outcome population. CNV ¼ choroidal neovascularization; FA ¼ ﬂuorescein angiography;
HSML ¼ high-density subthreshold micropulse laser treatment; PCV ¼ polypoidal choroidal vasculopathy; PDT ¼ photodynamic therapy; SRF ¼
subretinal ﬂuid.
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treatment at both short-term and long-term follow-up visits.
Moreover, functional outcomewas better after half-dose PDT
compared with HSML treatment with respect to both
increased retinal sensitivity at the ﬁrst and ﬁnal evaluation
visits and increased BCVA at the ﬁrst evaluation visit. In
contrast, the treatment groups did not differ signiﬁcantly with
respect to BCVA at the ﬁnal evaluation visit or to overall
quality of life (measured using the NEI-VFQ25). Our study
was designed primarily to assess a morphologic end point,
namely the complete resolution of SRF, which is a
prerequisite for preserving or restoring function, or both. In
this respect, microperimetry may be a more sensitive and
earlier functional end point than BCVA, given that the
recovery of BCVA can be delayed in cCSC after treatment.9
The signiﬁcantly better anatomic and functional outcomes
after PDT treatment may be attributed to the fact that PDT
targets the choroidal tissue, which seems to be the tissue pri-
marily affected in cCSC. In CSC, the accumulation of SRFd
which affects photoreceptor function and thus visiondresults
from a leaky outer blooderetina barrier at the level of theRPE;
however, this impaired barrier function is likely induced by a
primary dysfunction of the underlying choroid, given that
Table 1. Baseline Characteristics of Patients Included in Assessment of Primary Outcome Measure
Characteristics
Half-Dose Photodynamic
Therapy (n [ 80)
High-Density Subthreshold
Micropulse Laser Treatment (n [ 80) P Value
Demographics
Gender 0.072
Female 20 (25) 11 (13.8)
Male 60 (75) 69 (86.3)
Age (yrs) 48.98.9 48.68.3 0.819
Ethnicity
White 71 (88.8) 70 (87.5) 0.807
Other 9 (11.2) 10 (12.5)
Clinical characteristics
Duration of visual symptoms (mos) 6 (3.76e11) 6 (4e9.75) 0.796
Stress during month before visual symptoms started,
measured with the Cohen stress questionnaire
outcome on a scale from 0e40
14.77.4* 14.87.5 0.922
Best-corrected visual acuity (Early Treatment
Diabetic Retinopathy Study letters)
76.98.32 75.9 9.22 0.478
Retinal sensitivity on microperimetry (dB) 20.54.21 20.34.80 0.755
Composite score on vision-related quality of
life measured with the NEI-VFQ25
81.213.0 83.111.5 0.158
NEI-VFQ25 ¼ 25-item National Eye Institute Visual Function Questionnaire.
Data are no. (%), median (range), or mean  standard deviation.
*Data were available for 79 patients.





Micropulse Laser Treatment (n) P Value
Complete resolution of subretinal ﬂuid
At ﬁrst evaluation visit (at 6e8 wks after treatment) 51.2% (41/80) 13.8% (11/80) < 0.001
At ﬁnal evaluation visit (at 7e8 mos after treatment) 67.2% (45/67) 28.8% (19/66) < 0.001
Change in best-corrected visual acuity (Early Treatment
Diabetic Retinopathy Study letters)*
At ﬁrst evaluation visit (at 6e8 wks after treatment) þ4.606.62 (n ¼ 80) þ1.398.99 (n ¼ 80) 0.011
At ﬁnal evaluation visit (at 7e8 mos after treatment) þ6.788.54 (n ¼ 67) þ4.487.29 (n ¼ 66) 0.099
Change in retinal sensitivity on microperimetry (dB)*
At ﬁrst evaluation visit (at 6e8 wks after treatment) þ2.013.04 (n ¼ 76)y þ0.923.65 (n ¼ 77)y 0.046
At ﬁnal evaluation visit (at 7e8 mos after treatment) þ3.243.08 (n ¼ 62)y þ1.384.45 (n ¼ 60)y 0.008
Change in composite score on vision-related quality of life using
NEI-VFQ25 (on a scale from 0e100)*
At ﬁrst evaluation visit (at 6e8 wks after treatment) þ2.878.35 (n ¼ 80) þ2.567.36 (n ¼ 79)y 0.800
At ﬁnal evaluation visit (at 7e8 mos after treatment) þ7.0310.8 (n ¼ 67) þ4.489.85 (n ¼ 66) 0.158
NEI-VFQ25 ¼ 25-item National Eye Institute Visual Function Questionnaire.
Data are no. (%) or mean  standard deviation.
*Compared with baseline.
yData were not available for all patients.
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choroidal abnormalities (imaged using ICGA) often outweigh
both the changes in the RPE and leakage visible on FA. The
effect of PDT seems to depend on transient choroidal ischemia
and subsequent choroidal vascular remodelling23; in contrast,
the delivery of brief subthreshold micropulses to the RPE
during HSML treatment has been suggested to induce the
production of intracellular biological factors that stimulate
RPE function without causing visible damage to the retina.24
Given the signiﬁcant differences in treatment outcome
between half-dose PDT and HSML treatment in our study,
we suggest that choroidal abnormalities should be targeted in
cCSC.Nevertheless,whetherHSML treatment has therapeutic
effects on the choroid beyond the RPE currently is unknown.
None of the patients in either treatment group reported
treatment-relatedAEs. This ﬁnding is consistentwith previous
reports of extremely rare AEs when applying PDT at reduced
settings; such rare AEs include choroidal neovascularization
and occur in less than 1% of patients.11,14,25e28 Importantly,
choroidal neovascularization has also been described as part of
the natural course of cCSC.29
In this trial, the observed treatment outcome in both
treatment groups was likely the result of the intervention,
because we included only patients who showed SRF for at
least 6 weeks and who demonstrated typical ﬁndings of
active cCSC on multimodal imaging at presentation; thus,
SRF would not be expected to resolve spontaneously in
these patients. Moreover, we measured a signiﬁcant dif-
ference in outcome between the half-dose PDT group and
the HSML group. In the HSML treatment group, the laser
power was in the upper range of subthreshold settings, and
adjacent laser spots were treated to achieve conﬂuent
treatment coverage; in addition, the area to be treated was
relatively large and guided by ICGA. Despite these
measures to minimize undertreatment with HSML,21 the
outcome was still more favorable in the group that
received half-dose PDT. Importantly, the patients in the
PDT group received only half of the dose of verteporﬁn
originally described for treating neovascular age-related
macular degeneration8; this reduced dose was chosen
to minimize the occurrence of serious AEs after treatment
while still providing comparable treatment
outcomes.20,30,31 However, a distance of 500 mm from the
foveal center was kept only in the HSML-treated group to
prevent possible damage to the fovea, which has been
described to be a possible adverse effect of treatment and
could have inﬂuenced the results of our study. Still, we
assume that not including the fovea in the area to be treated
could have affected the study outcome only minimally
because the fovea included only a very small part of the
total area that required treatment; treatment often was quite
extensive because it was based on ICGA abnormalities
while using HSML settings at the upper limit for this
treatment technique.
The strengths of the PLACE trial include its prospective
design and the relatively large number of patients. In addi-
tion, we used the complete resolution of SRF on OCT as the
desired treatment effect, because the prolonged presence of
SRF can cause irreversible photoreceptor damage.6
Moreover, our cohort of cCSC patients was well
characterized, and the diagnosis of cCSC was veriﬁed in
each patient by a central reading center based on typical
ﬁndings of cCSC on multimodal imaging; in addition, we
excluded patients who had undergone previous cCSC
treatment, who had undergone previous or current
corticosteroid use, and whose disease duration was longer
than 18 months. These criteria resulted in a cohort of
patients who ranged from demonstrating relatively focal
cCSC to more extensive cCSC. Finally, with respect to
both anatomic and functional outcomes, a follow-up
assessment was performed 7 to 8 months after the ﬁrst
treatment; thus, prolonged follow-up studies should be
performed to assess the long-term efﬁcacy of both treat-
ments, particularly given that SRF recurred in 5 patients
during the follow-up period.
In conclusion, the results of our large prospective,
multicenter, randomized controlled treatment trial
showed that half-dose PDT provides superior outcome
compared with HSML treatment in patients with cCSC.
This ﬁnding provides key insight into developing best-
practice guidelines for treating CSC. In addition, the
results of this trial may be used to justify changing the
existing reimbursement restrictions in several countries
regarding the off-label use of verteporﬁn in PDT for
treating cCSC.










Serious adverse events* 2 (2 patients) 2 (2 patients)
No. of adverse events 12 (10 patients) 9 (7 patients)
Viral infectious disease of the
upper respiratory tract
0 3
Corneal erosion 2 0
Arthritis 1 0
Allergic response to verteporﬁn 1 0




Bladder cancer 1 0
Chalazion 0 1
Finger laceration 1 0
Gingivitis 1 0
Keratoconjunctivitis sicca 0 1









Uterine ﬁbroids 0 1
Vitamin D deﬁciency 0 1
YAG laser capsulotomy for
posterior capsule opaciﬁcation
0 1
Vision-threatening adverse events 0 1
*Note that none of the adverse events were related to the study treatment.
YAG ¼ yttrium aluminum garnet.
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